Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Squamous Cell Carcinoma of Head and Neck 25Head and Neck Neoplasms 17Salivary Gland Neoplasms 5Oropharyngeal Neoplasms 4Nasopharyngeal Carcinoma 4Melanoma 4Carcinoma, Renal Cell 4Sarcoma 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Recurrent Head and Neck Carcinoma 2Mouth Neoplasms 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Squamous Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Spinal Cord Compression 1Skin Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms, Unknown Primary 1Neoplasms, Squamous Cell 1Neoplasms 1Neoplasm Metastasis 1Laryngeal Diseases 1Kidney Neoplasms 1

Interventions

Cisplatin 30Magnetic Resonance Spectroscopy 21Radiotherapy 20pembrolizumab 18Specimen Handling 17Cetuximab 16Biopsy 13Radiotherapy, Intensity-Modulated 12Radiation 11Paclitaxel 11Carboplatin 11Surveys and Questionnaires 10Fluorouracil 10Drug Therapy 101,2-diaminocyclohexaneplatinum II citrate 10Platinum 9Surgical Procedures, Operative 8X-Rays 7Taxes 7Celecoxib 7Standard of Care 6Sentinel Lymph Node Biopsy 6Observation 5Nivolumab 5cemiplimab 4Metformin 4Interviews as Topic 4Immunohistochemistry 4Fluorodeoxyglucose F18 4Docetaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Mouth Neoplasms × Radiosurgery × Head & Neck × Clear all
NCT07156227 2026-06-03

Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 1 Recruiting
39 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT04576091 2024-12-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
7 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡